NM_015915.5:c.322A>G
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 1P and 10B. PP2BP4BP6BS1BS2
The NM_015915.5(ATL1):c.322A>G(p.Thr108Ala) variant causes a missense change. The variant allele was found at a frequency of 0.000103 in 1,613,956 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_015915.5 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary spastic paraplegia 3AInheritance: AD, SD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
- neuropathy, hereditary sensory, type 1DInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae)
- hereditary sensory and autonomic neuropathy type 1Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -9 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| ATL1 | NM_015915.5 | c.322A>G | p.Thr108Ala | missense_variant | Exon 3 of 14 | ENST00000358385.12 | NP_056999.2 | |
| ATL1 | NM_001127713.1 | c.322A>G | p.Thr108Ala | missense_variant | Exon 4 of 14 | NP_001121185.1 | ||
| ATL1 | NM_181598.4 | c.322A>G | p.Thr108Ala | missense_variant | Exon 3 of 13 | NP_853629.2 | ||
| ATL1 | XM_047431430.1 | c.322A>G | p.Thr108Ala | missense_variant | Exon 4 of 15 | XP_047287386.1 | 
Ensembl
Frequencies
GnomAD3 genomes  0.0000985  AC: 15AN: 152212Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.000163  AC: 41AN: 251250 AF XY:  0.000140   show subpopulations 
GnomAD4 exome  AF:  0.000103  AC: 151AN: 1461626Hom.:  0  Cov.: 30 AF XY:  0.000100  AC XY: 73AN XY: 727118 show subpopulations 
Age Distribution
GnomAD4 genome  0.0000985  AC: 15AN: 152330Hom.:  0  Cov.: 32 AF XY:  0.000107  AC XY: 8AN XY: 74490 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
not provided    Uncertain:1Benign:2 
- -
- -
In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 23334294) -
Hereditary spastic paraplegia 3A    Benign:2 
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -
- -
Inborn genetic diseases    Uncertain:1 
The p.T108A variant (also known as c.322A>G), located in coding exon 3 of the ATL1 gene, results from an A to G substitution at nucleotide position 322. The threonine at codon 108 is replaced by alanine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the supporting evidence, this variant is unlikely to be causative of autosomal dominant spastic paraplegia 3A or hereditary sensory neuropathy type ID; however, its contribution to the development of autosomal recessive spastic paraplegia 3A is uncertain. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at